Loading stock data…
$4.21-0.09 (-1.98%)
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
Vanda Pharmaceuticals Inc. in the Healthcare sector is trading at $4.21 with a market capitalization of $325M. Wall Street consensus targets $11.75 (5 analysts), implying a +178.8% move over the next 12 months. The stock is currently near its 52-week low of $4.20, remaining 34.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $50.53M↓ | $51.72M↓ | $57.22M↑ | $56.26M↑ | $52.59M |
| Gross Profit | $46.97M↓ | $48.56M↓ | $53.38M↑ | $53.30M↑ | $49.85M |
| Operating Income | -$63.81M↓ | -$50.22M↓ | -$40.35M↓ | -$31.28M↑ | -$38.50M |
| Net Income | -$62.51M↓ | -$48.57M↑ | -$141.19M↓ | -$22.59M↑ | -$27.21M |
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic ...